New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
06:33 EDTAVEOAveo and Astellas discontinue Phase 2 trial of tivozanib in breast cancer
Aveo and Astellas Pharma have jointly decided to discontinue the BATON - Biomarker Assessment of Tivozanib in ONcology - breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer, due to insufficient enrollment. All committed expenses related to the BATON-BC study are shared equally between AVEO and Astellas.
News For AVEO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
07:14 EDTAVEOAveo Pharmaceuticals to host conference call
Conference call to discuss presentation of final results and biomarker analysis from Phase 2 study of Tivozanib in Patients with Advanced Colorectal Cancer will be held on March 6 at 8 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use